IL3RA and acute myeloid leukemia: In our head- to-head comparison of CD123-specific CARs with CD28 and CD137co-stimulatory domains, we observed similar rates of target lysis with both constructs in vitro, though there was a trend toward better survival with the CD28-containing construct in our in vivo AML model.